178 related articles for article (PubMed ID: 23660171)
1. Nonrelapse mortality and mycophenolic acid exposure in nonmyeloablative hematopoietic cell transplantation.
McDermott CL; Sandmaier BM; Storer B; Li H; Mager DE; Boeckh MJ; Bemer MJ; Knutson J; McCune JS
Biol Blood Marrow Transplant; 2013 Aug; 19(8):1159-66. PubMed ID: 23660171
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation.
Giaccone L; McCune JS; Maris MB; Gooley TA; Sandmaier BM; Slattery JT; Cole S; Nash RA; Storb RF; Georges GE
Blood; 2005 Dec; 106(13):4381-8. PubMed ID: 16144801
[TBL] [Abstract][Full Text] [Related]
3. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.
Maris MB; Sandmaier BM; Storer BE; Maloney DG; Shizuru JA; Agura E; Kliem C; Pulsipher M; Maziarz RT; McSweeney PA; Wade J; Langston AA; Chauncey TR; Bruno B; Blume KG; Storb R
Biol Blood Marrow Transplant; 2006 Apr; 12(4):454-65. PubMed ID: 16545729
[TBL] [Abstract][Full Text] [Related]
4. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
5. Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning.
Baron F; Sandmaier BM; Storer BE; Maris MB; Langston AA; Lange T; Petersdorf E; Bethge W; Maziarz RT; McSweeney PA; Pulsipher MA; Wade JC; Chauncey TR; Shizuru JA; Sorror ML; Woolfrey AE; Maloney DG; Storb R
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1041-8. PubMed ID: 17697966
[TBL] [Abstract][Full Text] [Related]
6. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
7. A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients.
Windreich RM; Goyal RK; Joshi R; Kenkre TS; Howrie D; Venkataramanan R
Biol Blood Marrow Transplant; 2016 Apr; 22(4):682-689. PubMed ID: 26740371
[TBL] [Abstract][Full Text] [Related]
8. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
9. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.
Niederwieser D; Maris M; Shizuru JA; Petersdorf E; Hegenbart U; Sandmaier BM; Maloney DG; Storer B; Lange T; Chauncey T; Deininger M; Pönisch W; Anasetti C; Woolfrey A; Little MT; Blume KG; McSweeney PA; Storb RF
Blood; 2003 Feb; 101(4):1620-9. PubMed ID: 12393457
[TBL] [Abstract][Full Text] [Related]
10. Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases.
Georges GE; Maris M; Sandmaier BM; Malone DG; Feinstein L; Niederweiser D; Shizuru JA; McSweeney PA; Chauncey TR; Agura E; Little MT; Sahebi F; Hegenbart U; Pulsipher MA; Bruno B; Forman S; Woolfrey AE; Radich JP; Blume KG; Storb R
Int J Hematol; 2002 Aug; 76 Suppl 1():184-9. PubMed ID: 12430851
[TBL] [Abstract][Full Text] [Related]
11. An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients.
Bhatia M; Militano O; Jin Z; Figurski M; Shaw L; Moore V; Morris E; Tallamy B; van deVen C; Ayello J; Baxter-Lowe L; Satwani P; George D; Bradley MB; Garvin J; Cairo MS
Biol Blood Marrow Transplant; 2010 Mar; 16(3):333-43. PubMed ID: 19835971
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil.
Li H; Mager DE; Sandmaier BM; Storer BE; Boeckh MJ; Bemer MJ; Phillips BR; Risler LJ; McCune JS
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1121-9. PubMed ID: 24727337
[TBL] [Abstract][Full Text] [Related]
13. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation.
Jacobson P; Rogosheske J; Barker JN; Green K; Ng J; Weisdorf D; Tan Y; Long J; Remmel R; Sawchuk R; McGlave P
Clin Pharmacol Ther; 2005 Nov; 78(5):486-500. PubMed ID: 16321615
[TBL] [Abstract][Full Text] [Related]
14. Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.
Chhabra S; Liu Y; Hemmer MT; Costa L; Pidala JA; Couriel DR; Alousi AM; Majhail NS; Stuart RK; Kim D; Ringden O; Urbano-Ispizua A; Saad A; Savani BN; Cooper B; Marks DI; Socie G; Schouten HC; Schoemans H; Abdel-Azim H; Yared J; Cahn JY; Wagner J; Antin JH; Verdonck LF; Lehmann L; Aljurf MD; MacMillan ML; Litzow MR; Solh MM; Qayed M; Hematti P; Kamble RT; Vij R; Hayashi RJ; Gale RP; Martino R; Seo S; Hashmi SK; Nishihori T; Teshima T; Gergis U; Inamoto Y; Spellman SR; Arora M; Hamilton BK
Biol Blood Marrow Transplant; 2019 Jan; 25(1):73-85. PubMed ID: 30153491
[TBL] [Abstract][Full Text] [Related]
15. Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients.
McCune JS; Storer B; Thomas S; McKiernan J; Gupta R; Sandmaier BM
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1802-1807. PubMed ID: 29656138
[TBL] [Abstract][Full Text] [Related]
16. Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation.
Jacobson P; El-Massah SF; Rogosheske J; Kerr A; Long-Boyle J; DeFor T; Jennissen C; Brunstein C; Wagner J; Tomblyn M; Weisdorf D
Bone Marrow Transplant; 2009 Jul; 44(2):113-20. PubMed ID: 19151792
[TBL] [Abstract][Full Text] [Related]
17. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies.
Maris MB; Niederwieser D; Sandmaier BM; Storer B; Stuart M; Maloney D; Petersdorf E; McSweeney P; Pulsipher M; Woolfrey A; Chauncey T; Agura E; Heimfeld S; Slattery J; Hegenbart U; Anasetti C; Blume K; Storb R
Blood; 2003 Sep; 102(6):2021-30. PubMed ID: 12791654
[TBL] [Abstract][Full Text] [Related]
18. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
Feinstein L; Sandmaier B; Maloney D; McSweeney PA; Maris M; Flowers C; Radich J; Little MT; Nash RA; Chauncey T; Woolfrey A; Georges G; Kiem HP; Zaucha JM; Blume KG; Shizuru J; Niederwieser D; Storb R
Ann N Y Acad Sci; 2001 Jun; 938():328-37; discussion 337-9. PubMed ID: 11458521
[TBL] [Abstract][Full Text] [Related]
19. The combination of sirolimus plus tacrolimus improves outcome after reduced-intensity conditioning, unrelated donor hematopoietic stem cell transplantation compared with cyclosporine plus mycofenolate.
Perez-Simón JA; Martino R; Parody R; Cabrero M; Lopez-Corral L; Valcarcel D; Martinez C; Solano C; Vazquez L; Márquez-Malaver FJ; Sierra J; Caballero D
Haematologica; 2013 Apr; 98(4):526-32. PubMed ID: 23065527
[TBL] [Abstract][Full Text] [Related]
20. Use of mycophenolate mofetil and a calcineurin inhibitor in allogeneic hematopoietic stem-cell transplantation from HLA-matched siblings or unrelated volunteer donors: Japanese multicenter phase II trials.
Nakane T; Nakamae H; Yamaguchi T; Kurosawa S; Okamura A; Hidaka M; Fuji S; Kohno A; Saito T; Aoyama Y; Hatanaka K; Katayama Y; Yakushijin K; Matsui T; Yamamori M; Takami A; Hino M; Fukuda T
Int J Hematol; 2017 Apr; 105(4):485-496. PubMed ID: 27943166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
